John Moroney to Ovarian Neoplasms
This is a "connection" page, showing publications John Moroney has written about Ovarian Neoplasms.
Connection Strength
1.596
-
Safety and Clinical Activity of Atezolizumab Plus Bevacizumab in Patients with Ovarian Cancer: A Phase Ib Study. Clin Cancer Res. 2020 11 01; 26(21):5631-5637.
Score: 0.472
-
Phase I study of the antiangiogenic antibody bevacizumab and the mTOR/hypoxia-inducible factor inhibitor temsirolimus combined with liposomal doxorubicin: tolerance and biological activity. Clin Cancer Res. 2012 Oct 15; 18(20):5796-805.
Score: 0.273
-
Aflibercept in epithelial ovarian carcinoma. Future Oncol. 2009 Jun; 5(5):591-600.
Score: 0.218
-
NRG-GY012: Randomized phase 2 study comparing olaparib, cediranib, and the combination of cediranib/olaparib in women with recurrent, persistent, or metastatic endometrial cancer. Cancer. 2024 Apr 15; 130(8):1234-1245.
Score: 0.149
-
Mirvetuximab Soravtansine in FRa-Positive, Platinum-Resistant Ovarian Cancer. N Engl J Med. 2023 Dec 07; 389(23):2162-2174.
Score: 0.149
-
A phase 2 study of dasatinib in recurrent clear cell carcinoma of the ovary, fallopian tube, peritoneum or endometrium: NRG oncology/gynecologic oncology group study 0283. Gynecol Oncol. 2023 09; 176:16-24.
Score: 0.145
-
Epigenetic priming enhances antitumor immunity in platinum-resistant ovarian cancer. J Clin Invest. 2022 07 15; 132(14).
Score: 0.135
-
What is the benefit of bevacizumab combined with chemotherapy in patients with recurrent ovarian, fallopian tube or primary peritoneal malignancies? J Chemother. 2009 Nov; 21(5):566-72.
Score: 0.056